Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in England

Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in England

Abstract Introduction We sought to evaluate the cost-effectiveness of newborn screening (NBS) versus no NBS for 5q spinal muscular atrophy (SMA) in England. Methods A cost-utility analysis using a combination of decision tree and Markov model structures was developed to estimate the lifetime health...

Full description

Bibliographic Details
Main Authors: Diana Weidlich, Laurent Servais, Imran Kausar, Ruth Howells, Matthias Bischof
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-05-01
Series:Neurology and Therapy
Subjects:
Cost-effectiveness
Cost-utility analysis
Newborn screening
Nusinersen
Onasemnogene abeparvovec
Risdiplam
Online Access:https://doi.org/10.1007/s40120-023-00489-2

Internet

https://doi.org/10.1007/s40120-023-00489-2

Similar Items